BRISBANE, Calif., Dec. 28 /PRNewswire-FirstCall/ -- InterMune, Inc. announced today that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, upon being declared effective by the SEC, will allow InterMune to sell from time to time up to $175 million of its common stock, preferred stock, debt securities and warrants. The nature and terms of any offering will be established at the time of sale. Proceeds from the sale of any securities are expected to be used for general corporate purposes, which may include funding the company's research and development, increasing its working capital, reducing indebtedness, acquisitions or investments in businesses, products or technologies, and capital expenditures.
As part of the registration statement filed with the SEC, Warburg, Pincus Equity Partners, L.P. registered its 7,357,549 previously-issued shares of common stock. Warburg Pincus may be a selling stockholder, from time to time, in one or more offerings. InterMune will not receive any proceeds, and the number of InterMune shares outstanding will not change from such sales.
The registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state.
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.
